Asia Pacific Will Supplant US-Europe as Pharma Center

August 7, 2007 – A new PricewaterhouseCoopers study posits that Asia-Pacific countries will eventually be the center for global biopharma, shifting from the US-Europe axis that currently drives the sector. Multinational corporations are investing money into the East, while Asia-Pacific biopharmas are buying up assets to increase their own penetration of international markets. Multinationals are looking at Asian Pacific countries as more than markets or an inexpensive place to manufacture drugs. Asia Pacific has now become a place to do innovative research inexpensively. More details...